The prognostic significance of neuroendocrine differentiation in prostatic malignancy is controversial, but the results of recent studies with markers such as chromogranin A and neurone-specific enolase suggest that neuroendocrine differentiation, as reflected by increased tissue expression or blood concentrations of these neuroendocrine secretory products, is associated with a poor prognosis, tumour progression, and androgen independence. As all malignant neuroendocrine cells are devoid of androgen receptors and the expression of neuroendocrine cells is not suppressed by androgen ablation, clonal propagation of androgen receptor-negative neuroendocrine cells may have an important role in the development of androgen-independent prostatic carcinoma. This has significant implications for the treatment of prostate cancer, because several of the hormones that are secreted by neuroendocrine differentiated, malignant prostatic cells are potential candidates for use in drug treatment. A limited number of hormones have been tested in this context, in particular somatostatin, bombesin, and serotonin. As there is currently no successful treatment for differentiated prostate cancer, new therapeutic procedures and trials need to be developed to test drugs based on neuroendocrine hormones or their antagonists.

This article has been cited by other articles:

				R. J. Jin, Y. Lho, L. Connelly, Y. Wang, X. Yu, L. Saint Jean, T. C. Case, K. Ellwood-Yen, C. L. Sawyers, N. A. Bhowmick, et al. The Nuclear Factor-{kappa}B Pathway Controls the Progression of Prostate Cancer to Androgen-Independent Growth Cancer Res., August 15, 2008; 68(16): 6762 - 6769. [Abstract] [Full Text] [PDF]

				D. E. Frigo and D. P. McDonnell Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation Mol. Cancer Ther., March 1, 2008; 7(3): 659 - 669. [Abstract] [Full Text] [PDF]

				Z. Salah, M. Maoz, G. Pizov, and R. Bar-Shavit Transcriptional Regulation of Human Protease-Activated Receptor 1: A Role for the Early Growth Response-1 Protein in Prostate Cancer Cancer Res., October 15, 2007; 67(20): 9835 - 9843. [Abstract] [Full Text] [PDF]

				T.-C. Yuan, S. Veeramani, and M.-F. Lin Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells Endocr. Relat. Cancer, September 1, 2007; 14(3): 531 - 547. [Abstract] [Full Text] [PDF]

				S. Alessandro, G. Vincenzo, A. G. A. Maria, S. Stefano, G. Alessandro, M. Salvatore, T. Vincenzo, and D. S. Franco Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy Endocr. Relat. Cancer, September 1, 2007; 14(3): 625 - 632. [Abstract] [Full Text] [PDF]

				T.-C. Yuan, S. Veeramani, F.-F. Lin, D. Kondrikou, S. Zelivianski, T. Igawa, D. Karan, S. K. Batra, and M.-F. Lin Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr. Relat. Cancer, March 1, 2006; 13(1): 151 - 167. [Abstract] [Full Text] [PDF]

				S Humez, M Monet, G Legrand, G Lepage, P Delcourt, and N Prevarskaya Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells. Endocr. Relat. Cancer, March 1, 2006; 13(1): 181 - 195. [Abstract] [Full Text] [PDF]

				M. Ruscica, E. Dozio, S. Boghossian, G. Bovo, V. Martos Riano, M. Motta, and P. Magni Activation of the Y1 Receptor by Neuropeptide Y Regulates the Growth of Prostate Cancer Cells Endocrinology, March 1, 2006; 147(3): 1466 - 1473. [Abstract] [Full Text] [PDF]

				J. E. Ippolito, J. Xu, S. Jain, K. Moulder, S. Mennerick, J. R. Crowley, R. R. Townsend, and J. I. Gordon An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers PNAS, July 12, 2005; 102(28): 9901 - 9906. [Abstract] [Full Text] [PDF]

				S. Filleur, K. Volz, T. Nelius, Y. Mirochnik, H. Huang, T. A. Zaichuk, M. S. Aymerich, S. P. Becerra, R. Yap, D. Veliceasa, et al. Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer Cancer Res., June 15, 2005; 65(12): 5144 - 5152. [Abstract] [Full Text] [PDF]

				L Lemonnier, R Lazarenko, Y Shuba, S Thebault, M Roudbaraki, G Lepage, N Prevarskaya, and R Skryma Alterations in the regulatory volume decrease (RVD) and swelling-activated Cl-current associated with neuroendocrine differentiation of prostate cancer epithelial cells Endocr. Relat. Cancer, June 1, 2005; 12(2): 335 - 349. [Abstract] [Full Text] [PDF]

				A Berruti, A Mosca, M Tucci, C Terrone, M Torta, R Tarabuzzi, L Russo, C Cracco, E Bollito, R M Scarpa, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease Endocr. Relat. Cancer, March 1, 2005; 12(1): 109 - 117. [Abstract] [Full Text] [PDF]

				R. J. Jin, Y. Wang, N. Masumori, K. Ishii, T. Tsukamoto, S. B. Shappell, S. W. Hayward, S. Kasper, and R. J. Matusik NE-10 Neuroendocrine Cancer Promotes the LNCaP Xenograft Growth in Castrated Mice Cancer Res., August 1, 2004; 64(15): 5489 - 5495. [Abstract] [Full Text] [PDF]

				P. V. Nantermet, J. Xu, Y. Yu, P. Hodor, D. Holder, S. Adamski, M. A. Gentile, D. B. Kimmel, S.-i. Harada, D. Gerhold, et al. Identification of Genetic Pathways Activated by the Androgen Receptor during the Induction of Proliferation in the Ventral Prostate Gland J. Biol. Chem., January 9, 2004; 279(2): 1310 - 1322. [Abstract] [Full Text] [PDF]

				R. E. Bakin, D. Gioeli, R. A. Sikes, E. A. Bissonette, and M. J. Weber Constitutive Activation of the Ras/Mitogen-activated Protein Kinase Signaling Pathway Promotes Androgen Hypersensitivity in LNCaP Prostate Cancer Cells Cancer Res., April 15, 2003; 63(8): 1981 - 1989. [Abstract] [Full Text] [PDF]

				D. Farini, A. Puglianiello, C. Mammi, G. Siracusa, and C. Moretti Dual Effect of Pituitary Adenylate Cyclase Activating Polypeptide on Prostate Tumor LNCaP Cells: Short- and Long-Term Exposure Affect Proliferation and Neuroendocrine Differentiation Endocrinology, April 1, 2003; 144(4): 1631 - 1643. [Abstract] [Full Text] [PDF]

				R. M. Adam, J. Kim, J. Lin, A. Orsola, L. Zhuang, D. C. Rice, and M. R. Freeman* Heparin-Binding Epidermal Growth Factor-Like Growth Factor Stimulates Androgen-Independent Prostate Tumor Growth and Antagonizes Androgen Receptor Function Endocrinology, December 1, 2002; 143(12): 4599 - 4608. [Abstract] [Full Text] [PDF]

				L. D. True, K. Buhler, J. Quinn, E. Williams, P. S. Nelson, N. Clegg, J. A. Macoska, T. Norwood, A. Liu, W. Ellis, et al. A Neuroendocrine/Small Cell Prostate Carcinoma Xenograft--LuCaP 49 Am. J. Pathol., August 1, 2002; 161(2): 705 - 715. [Abstract] [Full Text] [PDF]

				M. D. Sadar, V. A. Akopian, and E. Beraldi Characterization of a New in Vivo Hollow Fiber Model for the Study of Progression of Prostate Cancer to Androgen Independence Mol. Cancer Ther., June 1, 2002; 1(8): 629 - 637. [Abstract] [Full Text] [PDF]

				J. Kim, R. M. Adam, and M. R. Freeman Activation of the Erk Mitogen-activated Protein Kinase Pathway Stimulates Neuroendocrine Differentiation in LNCaP Cells Independently of Cell Cycle Withdrawal and STAT3 Phosphorylation Cancer Res., March 1, 2002; 62(5): 1549 - 1554. [Abstract] [Full Text] [PDF]

				L.-F. Lee, J. Guan, Y. Qiu, and H.-J. Kung Neuropeptide-Induced Androgen Independence in Prostate Cancer Cells: Roles of Nonreceptor Tyrosine Kinases Etk/Bmx, Src, and Focal Adhesion Kinase Mol. Cell. Biol., December 15, 2001; 21(24): 8385 - 8397. [Abstract] [Full Text] [PDF]

				M. E. Taplin and S.-M. Ho The Endocrinology of Prostate Cancer J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3467 - 3477. [Full Text] [PDF]